Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23294574 | 0.86 | NPSR1 (0.33) | MAPTALDH1A1ELANEMAPK1SMN1; SMN2 | |
| SCHEMBL26849367 | 0.83 | DGAT1 (0.32) | — | |
| SCHEMBL23294376 | 0.82 | TARBP2 (0.47) | TARBP2MAPTCYP19A1ALDH1A1ELANE | |
| SCHEMBL31412644 | 0.78 | TARBP2 (0.36) | TARBP2MAPTCYP19A1ALDH1A1ELANE | |
| SCHEMBL31410579 | 0.78 | HTT (0.36) | MAPTALDH1A1MAPK1SMN1; SMN2CA1 | |
| SCHEMBL26677486 | 0.78 | DGAT1 (0.38) | — | |
| SCHEMBL22899721 | 0.77 | MAPT (0.37) | MAPTALDH1A1MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL23294607 | 0.77 | MAPT (0.41) | TARBP2MAPTCYP19A1ALDH1A1MAPK1 | |
| SCHEMBL23306468 | 0.77 | TARBP2 (0.36) | TARBP2MAPTCYP19A1ALDH1A1ELANE | |
| SCHEMBL29852224 | 0.77 | GABRG2 (0.40) | TARBP2MAPTCYP19A1ELANECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | Lilac Therapeutics, Inc. | 2024-03-21 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4051667-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929676-A | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
| WO-2021086874-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | GyanRx Sciences, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-20210128532-A1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | UGDH, PGD, PNPO | TARBP2 4367/4885MAPT 3488/4885CYP19A1 1204/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | TARBP2 4610/4885MAPT 3882/4885CYP19A1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.